Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) pre-open; what’s to expect from an oversold sector?

June 12, 2018 7:56am

The “news” ball is launched and rolling on the roulette table

But, there’s “short” money on the table!

Reiterating, “There is something lurking out there” – don’t get too comfortable with the sector and market. Volume continues low as volatility fluctuates.”

Pre-open indications: 6 BUYs

Out and about: Pluristem (PSTI) has an upside pre-market indication of +$0.41 or +29.29% after news of positive top-line results from its multinational P2 clinical study of PLX-PAD cells in the treatment of Intermittent Claudication (IC). PLX-PAD treatment reduced Incidence of revascularization and improved patients’ mobility. Study results also validate the design of PSTI’s ongoing Pivotal P3 study in CLI, a more severe stage of peripheral arterial disease (PAD) – BUY;

If you were a subscriber, and had read Monday’s closing “brief” you’d understand how today’s pre-open indications shed light on share pricing!

Members only. Please login.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.